We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Cellular Aging and Neurobiology of Depression Study (CAN-D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00285935
Recruitment Status : Recruiting
First Posted : February 2, 2006
Last Update Posted : March 17, 2022
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:

We are conducting an eight week longitudinal study to learn if blood levels of certain naturally occurring compounds and genetic markers differ between patients with depression and healthy adults who are not depressed, and if any such differences relate to memory performance, mood, and neurobiology.

We will do this by comparing the unmedicated depressed patients with matched healthy controls at baseline and then following the depressed patients over the course of eight weeks of standardized antidepressant treatment to gauge which baseline abnormalities normalize over the course of treatment.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Other: Standard Clinical Care with an SRRI Not Applicable

Detailed Description:

Following an initial telephone screen to assess inclusion and exclusion criteria, the evaluation will continue with an in-person evaluation to assess the presence or absence of active medical history and history of major psychiatric illness, as well as review of the consent document. If found to be eligible, participants would then be admitted to the study.

The next step for eligible, consenting depressed subjects and healthy controls is a baseline hospital visit and baseline MRI. The baseline hospital visit will last about 4 hours. We will begin the baseline visit by collecting a urine sample for a drug (and, for women, pregnancy) test. As long as that is negative, we will then collect a blood sample of about 155cc. After the blood draw, participants will complete cognitive tests and meet again with the study psychiatrist. Participants will also complete a baseline Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) of their brain at the Veteran's Affairs (VA) Hospital in San Francisco.

After the baseline hospital visit and MRI, depressed subjects (but not healthy controls) will begin taking an FDA approved antidepressant, as prescribed by the study psychiatrist, for the next 8 weeks while they are enrolled in the study. The specific drug will be decided upon between the participant and the study psychiatrist at the in-person screening visit.

After 4 weeks, depressed participants will return to UCSF to meet again with the psychiatrist to discuss symptoms and how to continue treatment; at that visit, they will have another blood draw of 155cc (the same blood draw as at baseline). Healthy controls will return at week 4 only for the blood draw.

4 weeks later (after 8 weeks in total), we will bring both depressed and healthy participants back for an additional visit that will include the same blood draw, testing, and MRI as the baseline visit. A physician-investigator will meet with the depressed subjects to review their clinical responses to treatment and to make further treatment suggestions, which the subjects may use in discussions of their future treatment options with their personal physicians. If a decision is made to discontinue antidepressant treatment, the subjects will be given instructions on how to withdraw from the medication, and will be given up to a 4 week supply of the drug to facilitate this withdrawal.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 228 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Neurosteroid Metabolism and the Antidepressant Effects of Serotonin Specific Reuptake Inhibitors (SSRI's)
Study Start Date : December 2010
Estimated Primary Completion Date : August 31, 2026
Estimated Study Completion Date : August 31, 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment with SSRI

Depressed participants will receive 8 weeks of treatment with one of the following serotonin-specific reuptake inhibitors:

fluoxetine (Prozac®), sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), escitalopram (Lexapro®)

The specific drug used for treatment will be selected by the study clinician based on clinical interviews and the participants preferences. Participants will be monitored for response and side effects by study clinician and will return after 8 weeks for a follow up study visit.

Other: Standard Clinical Care with an SRRI

Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label "treatment-as-usual" manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.

Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), escitalopram (Lexapro®)

Primary Outcome Measures :
  1. Depression ratings at baseline and Week 8 [ Time Frame: baseline and Week 8 ]
  2. Serum levels of steroids and neurosteroids at baseline and Week 8 [ Time Frame: baseline and Week 8 ]

Secondary Outcome Measures :
  1. Serum levels of oxidative stress markers at baseline and Week 8 [ Time Frame: baseline and Week 8 ]
  2. Serum levels of cytokines and immune markers at baseline and Week 8 [ Time Frame: baseline and Week 8 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

All participants must meet the following criteria:

  • Age 21-60 and able to give informed consent.
  • Not "needle phobic," by self-report.
  • English-speaking (to allow accurate use of behavioral rating scales and verbal cognitive tests).
  • Females of child-bearing capacity must be non-pregnant (confirmed by urine pregnancy test) and using effective non-hormonal birth control (e.g. abstinence, condoms, IUD).
  • • Good general medical health; no significant uncontrolled illnesses that will invalidate the designated outcome measures.
  • Clinical labs (electrolytes, liver function test, CBC) with no clinically significant abnormalities that result in medical treatment that will invalidate the designated outcome measures.
  • Negative urine toxicology (drugs of abuse) screen.
  • Taking no medication or drugs likely to interfere with the study objectives (including statins or medications that affect hormones [e.g. birth control pills or steroids]).
  • Free of all psychotropic medications (including antidepressants) for at least 6 weeks (with the exception of prn short-acting benzodiazepines or sedative-hypnotics, < 3 doses per week, and none for 5 drug half-lives before the study).
  • No vaccines for at least 4 weeks prior to baseline blood draw (including the flu shot).
  • Not currently anemic (Hct of 36-48 for females and 38-54 for males, or Hgb of 12.5-20) and has not donated blood for at least 8 weeks prior to baseline blood draw.
  • No MRI exclusions (e.g. severe claustrophobia, metal implants, pacemakers, BMI >38).
  • No neurological disorders and no history of concussion with a black-out that lasted > 10 minutes.

Additional criteria for Depressed Participants:

  • Current DSM-5 diagnosis of Major Depressive Disorder, unipolar, with non-psychotic features.
  • Baseline 17-item Hamilton Depression Rating Scale (HDRS) rating of >= 17, or Baseline 25-item HDRS rating of >= 20.
  • Current depressive episode duration of > 6 weeks.
  • No current, active suicidal intent; HDRS "suicidality" item rating <= 2 OR by clinician determination.
  • No recent (< 6 month) history of substance or alcohol use disorder(s), with the exception of tobacco use (DSM-5 criteria).
  • No current (in the last month) diagnosis of Post-Traumatic Stress Disorder (DSM-5 criteria).
  • No anticipated changes in psychotherapeutic interventions during the course of the study.

Additional criteria for Normal Controls:

• No history of DSM-5 Axis I diagnoses

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00285935

Layout table for location contacts
Contact: Mina Cheema, BS 415-476-72 candstudy@ucsf.edu

Layout table for location information
United States, California
University of California San Francisco Recruiting
San Francisco, California, United States, 94143-0984
Contact: Owen Wolkowitz, MD    415-476-7433    Owen.Wolkowitz@ucsf.edu   
Sponsors and Collaborators
University of California, San Francisco
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
Layout table for investigator information
Principal Investigator: Owen Wolkowitz, MD University of California, San Francisco
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00285935    
Other Study ID Numbers: 10-00825
R01MH083784 ( U.S. NIH Grant/Contract )
K08MH126192 ( U.S. NIH Grant/Contract )
First Posted: February 2, 2006    Key Record Dates
Last Update Posted: March 17, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of California, San Francisco:
Major Depressive Disorder
Selective Serotonin Reuptake Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms